Intellia Therapeutics
NTLA
NTLA
290 hedge funds and large institutions have $2.93B invested in Intellia Therapeutics in 2023 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 107 increasing their positions, 91 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
2.1% less ownership
Funds ownership: 91.54% → 89.45% (-2.1%)
4% less funds holding
Funds holding: 303 → 290 (-13)
28% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 47
Holders
290
Holding in Top 10
7
Calls
$18.7M
Puts
$12.4M
Top Buyers
| 1 | +$38.4M | |
| 2 | +$38.1M | |
| 3 | +$25.6M | |
| 4 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
+$22.1M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$16.3M |
Top Sellers
| 1 | -$47.7M | |
| 2 | -$18.6M | |
| 3 | -$17.7M | |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$17.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.5M |